Abound Wealth Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Abound Wealth Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$522	Sell	36 -6	-14%	-$81	﹤0.01%	942
2026 Q1	$582	Sell	42 -66	-61%	-$919	﹤0.01%	1042
2025 Q4	$1.52K	Buy	108 +6	+6%	+$84	﹤0.01%	878
2025 Q3	$1.43K	Buy	102 +7	+7%	+$101	﹤0.01%	839
2025 Q2	$1.43K	Sell	95 -8	-8%	-$114	﹤0.01%	779
2025 Q1	$1.36K	Sell	103 -24	-19%	-$331	﹤0.01%	734
2024 Q4	$2.01K	Buy	127 +2	+2%	+$30	﹤0.01%	672
2024 Q3	$1.99K	Buy	125 +35	+39%	+$563	﹤0.01%	708
2024 Q2	$1.37K	Hold	90	–	–	﹤0.01%	687
2024 Q1	$1.32K	Sell	90 -5	-5%	-$73	﹤0.01%	737
2023 Q4	$1.32K	Sell	95 -15	-14%	-$201	﹤0.01%	724
2023 Q3	$1.47K	Hold	110	–	–	﹤0.01%	663
2023 Q2	$1.39K	Buy	+110	New	+$1.28K	﹤0.01%	689

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Abound Wealth Management's RDY Position: Q2 2026 in Review

Abound Wealth Management reduced its Dr. Reddy's Laboratories (RDY) stake by 14% in Q2 2026, selling an estimated $81 and leaving 36 shares worth $522. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Abound Wealth Management first reported a position in RDY in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.01K in Q4 2024. 239 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

Abound Wealth Management held 36 shares of Dr. Reddy's Laboratories worth $522 as of Q2 2026.
Abound Wealth Management sold 6 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $81.
Dr. Reddy's Laboratories made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #942 holding.
Abound Wealth Management first reported a position in Dr. Reddy's Laboratories in Q2 2023 and has held it in 13 quarters since.
Abound Wealth Management's Dr. Reddy's Laboratories position peaked at $2.01K in Q4 2024.
239 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.